Heart attack

April 18, 2019

Intracardiac injection of Synthetic PreImplantation Factor (sPIF) promotes heart regeneration and repair: Intracardiac injection of Synthetic PreImplantation Factor (sPIF) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 18/April/2019, 8.01 am

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory […]
April 18, 2019

The anti-diabetic drug Canagliflozin protects against Myocardial Infarction and its associated complications: Canagliflozin (brand name: Invokana and Sulisent), a sodium -glucose co-transporter-2 inhibitor used in the treatment of TIIDM, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 18/April/2019, 6.50am

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of […]
April 9, 2019

Intracardiac injection of Cyclin helix B peptide (CHBP) protects against Myocardial infarction: Cyclin helix B peptide (CHBP) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 9/April/2019, 11.56 pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of […]
April 9, 2019

Carvedilol-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Carvedilol (Brand name: Coreg), a non-selective beta blocker used to treat congestive heart failure, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, , 9/April/2019, 11.17 pm

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]